Current Report Filing (8-k)
July 01 2019 - 6:17AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
May
30, 2019
Date
of Report (Date of earliest event reported)
Immune
Therapeutics, Inc.
(Exact
name of registrant as specified in its charter)
Florida
|
|
000-54933
|
|
59-3226705
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.
|
37
North Orange Ave, Suite 800M, Orlando, FL
|
|
32801
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code
888-613-8802
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.07 Submission of Matters to a Vote of Security Holders.
Immune
Therapeutics, Inc., a Florida corporation (the “Company”), sent a Proxy Statement on Schedule 14A to shareholder of
the Company on or around April 29, 2019 (the “Proxy Statement”). The Proxy Statement requested shareholders to vote
on the following corporate actions (collectively, the “Actions”):
|
(i)
|
Authorize
the Company to issue up to 10,000,000 shares of preferred stock, and designate 1,000,000 of such preferred shares as Series
D Preferred Stock;
|
|
|
|
|
(ii)
|
Effect
a reverse stock split of the Company’s issued and outstanding, but not authorized, common stock at a ratio between 800-to-1
and 1,000-to-1, to be determined by the Company’s Board of Directors and effectuated no later than December 31, 2019;
and
|
|
|
|
|
(iii)
|
Change
the Company’s name to Forte Biotechnology, Inc.
|
The
Company received all votes necessary to approve the Actions on May 30, 2019. This Current Report filed on Form 8-K (the “Current
Report”) is being filed solely to announce that the necessary votes have been received. As of the date of this Current Report,
none of the Actions have been effected.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
IMMUNE
THERAPEUTICS, INC.
|
|
|
|
Date:
July 1, 2019
|
By:
|
/s/
Noreen Griffin
|
|
|
Noreen
Griffin, CEO
|
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Apr 2023 to Apr 2024